Core Viewpoint - Century Huatong announced the cancellation of 1.28 million shares from its repurchase account, representing 0.0174% of the total share capital, reducing the total share capital from 7,371,962,322 shares to 7,370,682,322 shares [2] Summary by Category - **Share Repurchase Plan**: The shares canceled were part of a repurchase plan initiated in February 2022, which had a budget of 500 million to 1 billion yuan. The actual repurchase amounted to 1.28 million shares at a cost of 5.7324 million yuan [2] - **Change in Capital Structure**: The cancellation of these shares has been explicitly changed from being used for equity incentives or capital reduction to a definitive reduction in capital [2]

每经AI快讯，有投资者在投资者互动平台提问：公司有没有回购股份注销的可能？ 皖能电力（000543.SZ）12月24日在投资者互动平台表示，公司暂未有回购股份注销的计划。 （记者 曾健辉） ...

北京万泰生物药业股份有限公司（以下简称"公司"）于2025年10月15日召开第六届董事会第十次会议、 第六届监事会第十次会议，并于2025年10月31日召开2025年第一次临时股东会，审议并通过了《关于变 更部分回购股份用途并注销的议案》。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 统一社会信用代码：91110114600067778R 类型：其他股份有限公司（上市） 登录新浪财经APP 搜索【信披】查看更多考评等级 公司因回购专用证券账户中已回购但尚未使用的729,970股股份用途由"用于员工持股计划或股权激 励"变更为"用于注销并减少注册资本"。本次变更部分回购股份用途后，公司回购专用证券账户中的 729,970股已于2025年12月17日在中国证券登记结算有限责任公司完成注销。注销完成后公司总股本由 1,265,122,774股减少至1,264,392,804股，注册资本由1,265,122,774元减少至1,264,392,804元。具体内容详 见公司于2025年12月17日在指定信息披露媒体披露的《北京万泰生物 ...

Group 1 - The company completed the share repurchase and cancellation process, resulting in changes to its total share capital and the number of unrestricted circulating shares [1][2] - The company repurchased a total of 135,012,663 shares, accounting for 1.76% of the total share capital, with a total payment of approximately 10 billion yuan [2] - The repurchase plan's maximum amount of 10 billion yuan was reached, and the repurchase scheme has been fully implemented [2] Group 2 - Out of the repurchased shares, 95,000,000 shares will be canceled, reducing the registered capital, which represents 1.23% of the total share capital before cancellation [3] - The cancellation procedures for the 95,000,000 shares were completed on December 19, 2025, in compliance with relevant laws and regulations [3] - Following the cancellation, the company will amend its articles of association regarding registered capital and total shares, and will carry out necessary business registration changes [3]

证券日报网讯 12月22日晚间，美的集团发布公告称，公司本次累计回购股份135，012，663股，其中 95，000，000股将予以依法注销减少注册资本，注销股份占注销前总股本比例为1.23%。公司于2025年 12月19日在中国证券登记结算有限责任公司深圳分公司办理完毕上述95，000，000股回购股份注销手 续，注销数量、完成日期、注销期限均符合回购股份注销相关法律法规的规定。本次注销所回购的股份 不会对公司的财务状况和经营成果产生实质性影响。 （文章来源：证券日报） ...

阿特斯公告称，截至2025年12月22日，股东元禾重元已通过集中竞价和大宗交易方式减持公司股份 54,601,378股，占总股本1.50%，减持总金额7.78亿元，减持价格区间为9.60 - 23.49元/股。本次减持计划 时间已届满，未完成减持20,736,986股，当前持股比例降至0.57%。此外，公司于2025年12月19日注销 回购股份45,077,212股，总股本减少。 ...

Core Viewpoint - Midea Group announced a share buyback plan, with a total of 135 million shares repurchased, accounting for 1.76% of the company's total share capital, with a total expenditure of 10 billion yuan excluding transaction fees [1] Summary by Categories Share Buyback Details - The highest transaction price for the repurchased shares was 83.11 yuan per share, while the lowest was 69.91 yuan per share [1] - 70% or more of the repurchased shares will be used for cancellation and reduction of registered capital, with 95 million shares to be legally canceled [1] Impact on Capital Structure - The canceled shares will account for 1.23% of the total share capital before cancellation [1]

登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ● 北京万泰生物药业股份有限公司（以下简称"公司"）本次注销回购专用证券账户中已回购但尚未使用 的729,970股股份，本次注销完成后，公司总股本将由1,265,122,774股减少至1,264,392,804股。 ● 股份注销日：2025年12月17日 一、回购股份方案及实施情况 2022年8月5日，公司召开第五届董事会第十三次会议、第五届监事会第十三次会议，审议通过了《关于 以集中竞价交易方式回购公司股份方案的议案》，同意公司使用自有资金以集中竞价交易方式回购股份 用于员工持股计划或股权激励。具体内容详见公司于2022年8月6日、2022年8月13日在指定信息披露媒 体披露的《北京万泰生物药业股份有限公司关于以集中竞价交易方式回购公司股份方案的公告》（公告 编号：2022-070）、《北京万泰生物药业股份有限公司关于以集中竞价交易方式回购公司股份的回购报 告书》（公告编号：2022-072）。 2022年12月 ...

宋城演艺（300144）(300144.SZ)公告，公司拟回购公司股份用于注销并减少注册资本。回购股份的资 金总额不低于1亿元(含本数)且不超过2亿元(含本数)，回购价格上限为12.00元/股。回购股份的期限自公 司股东会审议通过本次回购方案之日起6个月内。 ...

Group 1 - The company held its 11th meeting of the 7th Board of Directors on December 8, 2025, where all 9 directors attended, and the meeting complied with legal and regulatory requirements [2][4][18] - The board approved the proposal to change the purpose of repurchased shares and to cancel 37,800,000 shares, which will be submitted to the first extraordinary general meeting of shareholders in 2025 for approval [3][5][11] - The board also approved the modification of the company's articles of association to reflect the cancellation of the repurchased shares, which will also be submitted to the shareholders' meeting [4][6][11] Group 2 - The company plans to change the purpose of the repurchased shares from being used for employee stock ownership plans to cancellation and reduction of registered capital, aimed at enhancing shareholder value [9][11][13] - Following the cancellation of the repurchased shares, the total share capital will decrease from 1,451,778,834 shares to 1,413,978,834 shares [12] - The company will hold the first extraordinary general meeting of shareholders on December 24, 2025, to discuss the approved proposals [16][19]